What is the 13F Pro Quality Score for NXGL?

13F Pro ranks NEXGEL, INC. (NXGL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NXGL's current score at https://13fpro.ai/company/NXGL (free sign-up required for the full ranking).

Where does 13F Pro source NXGL data?

All NEXGEL, INC. fundamentals and ownership data come directly from SEC EDGAR. NEXGEL, INC. files with the SEC under CIK 1468929. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NXGL in?

NEXGEL, INC. (NXGL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NXGL research updated on 13F Pro?

NXGL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

NEXGEL, INC.(NXGL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1468929 NXGL stock profile & AI dashboard →

13F Pro Quality Score

34.1/100

Rank #2,361 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why NXGL Scores 34/100

exact factor attribution · 2026-09-11

NXGL's composite is driven by revenue growth, held back by scale and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.6 pts

93th pct

Earnings quality

-0.6 pts

44th pct

Shareholder dilution

-1.1 pts

27th pct

Institutional flow

-1.3 pts

25th pct

Earnings growth

-1.7 pts

16th pct

Capital efficiency

-3.7 pts

13th pct

Free cash flow

-4.8 pts

18th pct

Profitability

-5.0 pts

17th pct

Scale

-6.2 pts

8th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

NXGL Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for NEXGEL, INC. (NXGL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NXGL at 34.1/100 on a 32-signal composite quality model, placing it at rank #2,361 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), NEXGEL, INC. reports quarterly revenue of $3.7M, net income of $-3.6M. Top institutional holders of NXGL by reported 13-F value include SUSQUEHANNA INTERNATIONAL GROUP, LLP, Virtu Financial, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. NXGL trades on the Nasdaq exchange and files with the SEC under CIK 1468929. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NXGL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NEXGEL, INC. directly from SEC EDGAR. NEXGEL, INC.'s 13F Pro composite quality score has ranged between 31 and 34 since 2026, currently 34.1 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about NEXGEL, INC.

Quirks, history, and lore behind NXGL — the kind of stuff that makes a stock memorable.

1
The Basics
A micro-cap healthcare company headquartered in Pennsylvania, listed on Nasdaq, focused on advanced material science for consumer and medical applications.
2
The Numbers
With annual revenues in the low millions, this is a small but scrappy operation — the kind of company where a single new contract can move the stock meaningfully.
3
The History
The company evolved its core technology from cooling and comfort products into a broader platform, pivoting toward pharmaceutical and medical-grade applications in recent years.
4
The Secret
Its secret weapon is a proprietary high-water-content hydrogel — a squishy, skin-friendly material that can deliver drugs, cooling, or wound care depending on what you need it to do.
5
The Lore
The company has licensed its hydrogel platform to consumer brands and is pursuing partnerships in topical drug delivery — because apparently the future of medicine is gloriously goopy.
6
The Giveaway
Ticker starts with NX, the name starts with NEX, and the whole business is built around a gel so hydrated it makes cucumbers jealous — this is the hydrogel pure-play of the public markets.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$3.7M

Net Income

Q2 2026

$-3.6M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+31.5% YoY

$11.4MFY 2025

FY22 $2.0MFY23 $4.1MFY24 $8.7MFY25 $11.4M

Net Income

+8.6% YoY

$-3.0MFY 2025

FY22 $-4.7MFY23 $-3.2MFY24 $-3.3MFY25 $-3.0M

Operating Income

+5.7% YoY

$-3.4MFY 2025

FY22 $-3.3MFY23 $-3.5MFY24 $-3.6MFY25 $-3.4M

EPS (Diluted)

+24.0% YoY

$-0.38FY 2025

FY22 $-0.85FY23 $-0.56FY24 $-0.50FY25 $-0.38

Total Assets

-4.8% YoY

$10.5MFY 2025

FY22 $10.4MFY23 $10.0MFY24 $11.0MFY25 $10.5M

Total Debt

-14.2% YoY

$588.0KFY 2025

FY22 $283.0KFY23 $838.0KFY24 $685.0KFY25 $588.0K

Op. Cash Flow

+66.1% YoY

$-1.3MFY 2025

FY22 $-3.0MFY23 $-3.2MFY24 $-3.9MFY25 $-1.3M

Free Cash Flow

+68.0% YoY

$-1.4MFY 2025

FY22 $-3.1MFY23 $-3.9MFY24 $-4.3MFY25 $-1.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$11.4M +31.5%	$8.7M +112.5%	$4.1M +99.7%	$2.0M +32.0%	$1.6M +130.1%	$674.0K
Net Income	$-3.0M +8.6%	$-3.3M -3.9%	$-3.2M +33.5%	$-4.7M -10.1%	$-4.3M -90.4%	$-2.3M
Operating Income	$-3.4M +5.7%	$-3.6M -2.2%	$-3.5M -3.9%	$-3.3M -30.3%	$-2.6M -13.7%	$-2.3M
EPS (Diluted)	$-0.38 +24.0%	$-0.50 +10.7%	$-0.56 +34.1%	$-0.85 +41.4%	$-1.45 -38.1%	$-1.05
Total Assets	$10.5M -4.8%	$11.0M +10.3%	$10.0M -3.9%	$10.4M -39.0%	$17.0M +652.5%	$2.3M
Total Debt	$588.0K -14.2%	$685.0K -18.3%	$838.0K +196.1%	$283.0K	—	—
Operating Cash Flow	$-1.3M +66.1%	$-3.9M -19.5%	$-3.2M -8.2%	$-3.0M -8.7%	$-2.8M -52.9%	$-1.8M
Free Cash Flow	$-1.4M +68.0%	$-4.3M -9.6%	$-3.9M -27.3%	$-3.1M -2.2%	$-3.0M -43.0%	$-2.1M

AI Insight: NXGL Financial Trends

Revenue inflection to $4M in Q2 2026 undermined by sharply wider losses and cash burn.

• Revenue rose to $4M in Q2 2026, ending five quarters of flat $3M run-rate.

• Net income loss widened to $4M in Q2 2026 from consistent $1M quarterly losses prior.

• Operating cash flow deteriorated to negative $2M in Q2 2026, worst in six quarters.

⚠ Q2 2026 margin collapse: operating loss $3M on $4M revenue (negative 75%) signals cost structure misalignment.

⚠ Debt stable at $1M but equity eroded to $4M—total debt-to-equity now 25%, highest since Q3 2024.

AI Insight: NXGL Ratio Trends

NEXGEL has deteriorated sharply into Q2 2026, with operating margin collapsing to -68.0% and net profit margin to -98.6%, signaling severe operational distress.

• Operating margin worsened from -24.7% in Q3 2025 to -68.0% in Q2 2026, a 43.3pp decline in six months.

• Net profit margin fell to -98.6% in Q2 2026 from -22.3% in Q3 2025, indicating accelerating cash burn.

• Return on assets dropped to -55.0% in Q2 2026 from -22.5% in Q3 2025, reflecting severely impaired asset efficiency.

⚠ Q4 2025 marked a turning point: ROIC crashed to -96.2% from -50.0% in Q3 2025, heralding continued deterioration.

⚠ D/E ratio stable ~0.12–0.14 masks underlying profitability collapse; leverage metrics unreliable without positive earnings.

Get alerted when NXGL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NEXGEL, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NXGL

SUSQUEHANNA INTERNATIONAL GROUP, LLP
$42.7K85,140 sh
Virtu Financial LLC
$40.0K79,128 sh
GEODE CAPITAL MANAGEMENT, LLC
$36.0K71,863 sh
HRT FINANCIAL LP
$34.0K69,485 sh
MORGAN STANLEY
$27.5K54,980 sh
VANGUARD CAPITAL MANAGEMENT LLC
$24.5K48,920 sh
ARMISTICE CAPITAL, LLC
$21.2K550,000 sh
CITADEL ADVISORS LLC
$20.5K40,976 sh
VANGUARD FIDUCIARY TRUST CO
$17.1K34,040 sh
UBS Group AG
$12.4K24,735 sh

Fund	Value	Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$42.7K	85,140
Virtu Financial LLC	$40.0K	79,128
GEODE CAPITAL MANAGEMENT, LLC	$36.0K	71,863
HRT FINANCIAL LP	$34.0K	69,485
MORGAN STANLEY	$27.5K	54,980
VANGUARD CAPITAL MANAGEMENT LLC	$24.5K	48,920
ARMISTICE CAPITAL, LLC	$21.2K	550,000
CITADEL ADVISORS LLC	$20.5K	40,976
VANGUARD FIDUCIARY TRUST CO	$17.1K	34,040
UBS Group AG	$12.4K	24,735

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NXGL on your watchlist

Track score changes the day NEXGEL, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NXGL a good stock to buy?

13F Pro's AI-powered analysis of NEXGEL, INC. (NXGL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NXGL are available on the NXGL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NXGL is classified as a small company.

Which hedge funds own NXGL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NXGL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NEXGEL, INC.'s investment landscape.